Product Description: Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912./[2]Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107.
CAS Number: 1461640-62-9
Molecular Weight: N/A
Compound Purity: 98.5
Research Area: Cancer
Solubility: H2O
Target: Apoptosis
English
Deutsch
